Eli Lilly's experimental weight-loss pill showed superior blood sugar control in diabetic patients across two late-stage ...

The company has announced positive data from the ACHIEVE-2 and ACHIEVE-5 trials, with both meeting all their primary and key ...

Eli Lilly said on Wednesday its experimental pill, orforglipron, helped reduce blood sugar levels in two late-stage trials.

Eli Lilly and Company's strong Phase 3 diabetes drug results boost its GLP-1 franchise. Click for my updated look at LLY ...

Eli Lilly stock has recovered resoundingly, outperforming the S&P 500, Novo Nordisk, and healthcare peers after a period of ...

A Lilly experimental weight loss pill showed superior blood sugar control in diabetic patients across two late-stage clinical ...

Eli Lilly said its investigational oral GLP-1 weight-loss drug, orforglipron, met its primary endpoints in two recent phase 3 trials. The medicine company said Wednesday the drug met the primary and ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Lilly is looking to build four pharmaceutical plants across the country. Two announcements are in the works.

Six months after his abrupt resignation as CBER director, Marks has been hired to run discovery and infectious disease work ...

After beating Novo Nordisk’s semaglutide last month, Lilly’s much anticipated oral candidate orforglipron has taken down AstraZeneca’s Farxiga in a head-to-head trial.

Elecsys’ approval could help boost the uptake of currently approved Alzheimer’s disease therapies, including Biogen’s ...